These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17200979)

  • 1. Recommended criteria for the mass spectrometric identification of target peptides and proteins (<8 kDa) in sports drug testing.
    Thevis M; Loo JA; Loo RR; Schänzer W
    Rapid Commun Mass Spectrom; 2007; 21(3):297-304. PubMed ID: 17200979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometric determination of insulins and their degradation products in sports drug testing.
    Thevis M; Thomas A; Schänzer W
    Mass Spectrom Rev; 2008; 27(1):35-50. PubMed ID: 18000882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry in sports drug testing: Structure characterization and analytical assays.
    Thevis M; Schänzer W
    Mass Spectrom Rev; 2007; 26(1):79-107. PubMed ID: 16888758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometric identification of peptide hormones in doping-control analysis.
    Thevis M; Schänzer W
    Analyst; 2007 Apr; 132(4):287-91. PubMed ID: 17554406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry.
    Thevis M; Thomas A; Delahaut P; Bosseloir A; Schänzer W
    Anal Chem; 2006 Mar; 78(6):1897-903. PubMed ID: 16536426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
    Thomas A; Schänzer W; Delahaut P; Thevis M
    Methods; 2012 Feb; 56(2):230-5. PubMed ID: 21871962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs and methods of doping and manipulation.
    Thevis M; Kohler M; Schänzer W
    Drug Discov Today; 2008 Jan; 13(1-2):59-66. PubMed ID: 18190865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Applications and progresses of liquid chromatography-mass spectrometry in doping control].
    Qin Y; Xu Y; Yang S; Zhu S
    Se Pu; 2008 Jul; 26(4):431-6. PubMed ID: 18959237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS.
    Thomas A; Geyer H; Kamber M; Schänzer W; Thevis M
    J Mass Spectrom; 2008 Jul; 43(7):908-15. PubMed ID: 18563864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine.
    Schänzer W; Geyer H; Fusshöller G; Halatcheva N; Kohler M; Parr MK; Guddat S; Thomas A; Thevis M
    Rapid Commun Mass Spectrom; 2006; 20(15):2252-8. PubMed ID: 16804957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteases in doping control analysis.
    Thevis M; Maurer J; Kohler M; Geyer H; Schänzer W
    Int J Sports Med; 2007 Jul; 28(7):545-9. PubMed ID: 17525883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis.
    Thevis M; Thomas A; Kohler M; Beuck S; Schänzer W
    J Mass Spectrom; 2009 Apr; 44(4):442-60. PubMed ID: 19373874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trends in mass spectrometry of peptides and proteins: Application to veterinary and sports-doping control.
    van den Broek I; Blokland M; Nessen MA; Sterk S
    Mass Spectrom Rev; 2015; 34(6):571-94. PubMed ID: 24375671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doping control analysis of selected peptide hormones using LC-MS(/MS).
    Thevis M; Thomas A; Schänzer W
    Forensic Sci Int; 2011 Dec; 213(1-3):35-41. PubMed ID: 21752560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Thevis M; Kohler M; Thomas A; Schlörer N; Schänzer W
    Rapid Commun Mass Spectrom; 2008 Aug; 22(16):2471-8. PubMed ID: 18634123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.
    Thevis M; Schänzer W
    Rapid Commun Mass Spectrom; 2016 Mar; 30(5):635-51. PubMed ID: 26842585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes.
    Thevis M; Thomas A; Fusshöller G; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2010 Aug; 24(15):2245-54. PubMed ID: 20623476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
    Bredehöft M; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis.
    Thevis M; Kohler M; Maurer J; Schlörer N; Kamber M; Schänzer W
    Rapid Commun Mass Spectrom; 2007; 21(21):3477-86. PubMed ID: 17985352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry of selective androgen receptor modulators.
    Thevis M; Schänzer W
    J Mass Spectrom; 2008 Jul; 43(7):865-76. PubMed ID: 18521833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.